NCT00025181View on ClinicalTrials.gov

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

January 31, 2003

Study Completion Date

June 30, 2005

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

MART-1 antigen

BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

ipilimumab

BIOLOGICAL

tyrosinase peptide

PROCEDURE

adjuvant therapy

Trial Locations (1)

90089

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT00025181 - Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery | Biotech Hunter | Biotech Hunter